The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final overall survival (OS) analysis of a multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-RT) without elective nodal irradiation with chemotherapy using cisplatin (CDDP) and vinorelbine (VNR) in patients with stage III non-small cell lung cancer (NSCLC).
 
Hidehito Horinouchi
Honoraria - Johnson & Johnson; Lilly; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical (Inst)
 
Ikuo Sekine
No Relationships to Disclose
 
Minako Sumi
No Relationships to Disclose
 
Toshinori Soejima
No Relationships to Disclose
 
Miyako Satouchi
Honoraria - Kyowa Hakko Kirin
Research Funding - Bristol-Myers Squibb; Kyowa Hakko Kirin
 
Hisayasu Nagakura
No Relationships to Disclose
 
Hiroshi Isobe
No Relationships to Disclose
 
Noriaki Nishiyama
No Relationships to Disclose
 
Masao Harada
No Relationships to Disclose
 
Naoki Ishizuka
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
Honoraria - Lilly
 
Tomohide Tamura
Honoraria - Astellas Pharma; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yuichiro Ohe
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche Pharma AG; Sanofi; Taiho Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly Japan; Novartis; Ono Pharmaceutical; Roche Pharma AG
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)